The Central Drugs Standards Control Organization (CDSCO) on January 16, 2025, issued a Guidance Document Validation of Rapid Diagnostics for Pathogen Identification and Antimicrobial Susceptibility Testing (AST) 2025.
It outlines a comprehensive framework for ensuring the accuracy, reliability, and clinical utility of rapid diagnostic tests. It emphasizes the need for robust validation processes to evaluate test performance, including analytical sensitivity, specificity, reproducibility, and robustness. The document provides guidelines on selecting appropriate reference methods, designing validation studies, and defining acceptance criteria to ensure consistency with regulatory and clinical standards. It also stresses the importance of considering diverse clinical scenarios and pathogen profiles during validation to maximize real-world applicability.
Additionally, the document highlights the integration of rapid diagnostics into antimicrobial stewardship programs to improve patient outcomes and combat antimicrobial resistance. Key recommendations include validating tests for timely and accurate identification of pathogens and their susceptibility profiles, thus enabling targeted therapy. Stakeholders, including diagnostic manufacturers, clinical laboratories, and regulatory agencies, are encouraged to collaborate in the development and validation of these tests, ensuring they meet the needs of both clinicians and patients while adhering to global best practices.
